How do you pronounce Elon and DOGE?
Why are AbbVie executives feeling the M&A blues? What does it take to slice $12 billion from Amgen's market value? And why are STAT's D.C. correspondents working so hard?
We talk about all that and more on this week's episode of the "The Readout LOUD," STAT's biotech podcast. It's a "Chatty Cathy" episode! Elaine, Allison and Adam lead off with a discussion about AbbVie's M&A miscue following the failure of a closely followed schizophrenia drug. You'd hate us if obesity drugs weren't mentioned, so we oblige with a tick-tock on what went down between Amgen and a Wall Street analyst who noted a possible safety issue with the obesity drug candidate MariTide. LISTEN NOW For more on what Trump's second term means for the FDA, go here; to learn about the key figures in the MAHA movement, go here; and for more on how leaders in the biopharma industry have reacted to the election, go here. Be sure to sign up for "The Readout LOUD" on Apple Podcasts, Spotify, TuneIn, or wherever you get your podcasts. Subscribe to the podcast to never miss an episode Visit the archive to see past episodes |
|
| STAT, 1 Exchange Place, Boston, MA | ©2024, All Rights Reserved. | |
|
No comments